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Nearly four years after the United States Congress heralded a “decade of pain control and research”, chronic pain
remains a mounting public health concern worldwide. The escalating prevalence of chronic pain in recent years
has been paralleled by a rise in prescription opioid availability, misuse, and associated human and social costs.
However, national monitoring surveys in the U.S. and Canada currently fail to differentiate between prescription
opioid misuse for the purposes of euphoria versus pain or withdrawal management. Furthermore, there is a lack of
evidence-based guidelines for pain management among high-risk individuals, and a glaring lack of education for
practitioners in the areas of pain and addiction medicine. Herein we propose multiple avenues for intervention
and research in order to mitigate the individual, social and structural problems related to undertreated pain and
prescription opioid misuse.
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Nearly four years after the U.S. Congress heralded a
“decade of pain control and research” (for the period of
2001 to 2010) [1-3], chronic pain management remains
a mounting public health concern worldwide. Globally,
over 1.5 billion people suffer from chronic pain [4]. In
the U.S., pain is the most common reason for seeking
medical care [5-7], and the 100 million Americans suf-
fering from chronic pain outweighs the number of
Americans with diabetes, heart disease, stroke and can-
cer combined [8-11]. In Canada, the estimated preva-
lence of chronic pain is between 15-29% [12-14].
Consequently, the cost of pain due to lost productivity
and health care costs is estimated to range at least
$560-635 billion USD annually [8].
The escalating problem of chronic pain has been paral-
leled by a distinct rise in prescription drug misuse particu-
larly in North America [15], with a 140.5% increase in
reported prescription drug misuse among the U.S. popula-
tion from 7.8 million in 1992 to 15.1 million in 2003. This
represents approximately 6% of the U.S. population, which* Correspondence: uhri-tk@cfenet.ubc.ca
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stated.exceeds the combined number of people in the U.S. who
use cocaine, hallucinogens, inhalants, and heroin com-
bined [16]. Canadian data, which have only recently been
collected at a national level, estimate that approximately
4.8% of the general population used prescription opioids
non-medically in 2009 [17,18]. As the demand for pre-
scription opioids (POs) has risen, so has the availability of
diverted POs and the prevalence of morbidities and mor-
talities associated with opioid use [19].
Importantly, of the 4.8% of the Canadian population
that reported nonmedical PO use, only 2.3% (0.4% of the
Canadian population) reported using POs “to get high”
[17]. Thus, the remaining majority of nonmedical PO
use can be attributed to factors that have been underex-
plored [16]. One such factor that may be fuelling the in-
creasing demand for and availability of diverted POs is
undertreated pain. One recent systematic review and
meta-analysis found a 48% pooled prevalence of pain
among PO misusers [20], and several studies have dem-
onstrated a positive association between chronic pain
and non-medical PO use [21,22], particularly among in-
dividuals with a history of substance misuse [23,24] who
are significantly more likely to receive inadequate pain
management within clinical settings [25,26]. Distinctions
between PO use for euphoria versus pain or withdrawalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ately addressed [27], since the latter may be effectively
managed with medical treatment regimes (e.g., opioid
agonist therapies, directly observed treatment) that may
allay PO misuse and diversion. Herein, we outline sev-
eral priority recommendations that may serve to miti-
gate the growing health and social costs of prescription
opioid misuse.
Main text
Re-defining “nonmedical prescription opioid use”
The U.S. National Survey on Drug Use and Health
(NSDUH) defines nonmedical PO use (NMPOU) as “use
without a prescription of the individual’s own or simply
for the experience or feeling the drugs cause”, while the
Canadian Alcohol and Drug Use Monitoring Survey
(CADUMS) defines NMPOU as past-year PO use “on at
least one occasion to get high [or] obtained from a pre-
scription written for someone else, bought from some-
one else, or obtained from any other source” [28,29].
Alternatively, the U.S. National Epidemiologic Survey on
Alcohol and Related Conditions (NESARC) defines
NMPOU as use “to feel more alert, to relax or quiet
nerves, to feel better, to enjoy [oneself], to get high or
just to see how [POs] would work” [30]. These varying
and complex definitions “rely on a mix of objective and
subjective measures that are difficult to verify” [29], such
as subjective PO use measures including “to feel better”
(NESARC) or “simply for the experience or feeling the
drugs cause” (NSDUH) combined with objective PO use
measures such as the individual’s source of POs [28,30].
These definitions are also problematic because they ag-
gregate motives for and means of possessing POs into
one definition and assume that PO use is a largely “non-
medical” issue despite the small proportion of PO use
for euphoria [17], while the majority of PO use may be
the result of medical issues such as undertreated pain or
withdrawal. Thus, current definitions of NMPOU may
lead to inaccurate data collection, interpretation, and
counterproductive approaches such as denying POs to
those with undertreated pain or withdrawal.
An improved definition may be derived from the U.S.
Monitoring the Future (MTF) survey, which simply de-
fines NMPOU as PO use “without a doctor’s orders dur-
ing the past 12 months” and later differentiates various
motives for PO use in the survey instrument [31]. How-
ever, this definition may not capture those who have aTable 1 Suggested definition to replace “nonmedical prescrip
Suggested definition Description
Not-as-prescribed opioid use (NAPOU) The authors suggest the term n
use may not be “nonmedical” in
not as indicated for the individu
own prescription outside of prelegitimate prescription but may take their medications
not as indicated (e.g., increased dose or frequency, or al-
ternate route or indication for administration). There-
fore, we suggest the term “not-as-prescribed opioid use”
(NAPOU), which recognizes that opiate use may not be
“nonmedical” in nature, and includes opioid use not as
indicated for the individual whether by use of someone
else’s prescription or use of one’s own prescription out-
side of prescribed parameters (Table 1). Within this
broader definition, in-depth data collection should be under-
taken to dichotomize the various motives for (e.g., euphoria
versus pain versus withdrawal) and means of PO use
(e.g., diverted medication from street-based markets,
use of another’s prescription, use of one’s own pre-
scription outside of prescribed parameters).
Developing evidence-based guidelines for pain management
among high-risk individuals
Despite the high prevalence of pain among individuals
with substance use disorders and psychosocial comor-
bidities [32,33], there is a severe lack of evidence to in-
form clinical guidelines for pain management among
these complex populations. For instance, the American
Pain Society’s guidelines for chronic pain management
explicitly state that their recommendations for high-risk
individuals are based on “low-quality evidence” and “an-
ecdotal experience” [34]. While these guidelines reflect
the state of evidence at the time (2009), there remains a
paucity of high-quality research on effective pain man-
agement approaches among substance-using popula-
tions. This is reflected by the Cochrane Collaboration’s
review on long-term opioid management for chronic
non-cancer pain, in which the majority of studies reviewed
excluded participants with a history of substance use
[35]. Therefore, high-quality research on pain manage-
ment for individuals with a history of substance use is
urgently needed to inform evidence-based clinical practice
guidelines.
Educating practitioners in pain and addiction medicine
A U.S.-wide audit found that 40% of physicians and 48%
of pharmacists received formal training in identifying
prescription drug abuse, yet 74% of physicians and 83%
of pharmacists refused to prescribe or dispense a con-
trolled drug due to concerns regarding addiction, diver-
sion or misuse [16]. Deficiencies in practitioner training
in pain and addiction medicine likely contribute totion opioid use”
ot-as-prescribed opioid use (NAPOU), which recognizes that opioid
nature (e.g., undertreated pain or withdrawal), and includes opioid use
al whether by the use of someone else’s prescription or the use of one’s
scribed parameters (e.g., alternate dose, frequency, route, or indication).
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misuse epidemic [36]. For example, a lack of clinician
training to inform patients about safe handling of POs
may be contributing to the majority of adolescents (74%)
with unsupervised access to prescription medications
[37]. Furthermore, a recent policy by the U.S. Food and
Drug Administration has required manufacturing com-
panies to develop Risk Evaluation and Mitigation Strat-
egies that involve providing education to patients and
providers on the safe use and prescribing of extended-
release and long-acting opioids, but this policy has not
been effectively translated into clinical practice [38].
Therefore, pain and addiction training should be in-
cluded in core medical school and residency curricula,
and pain and addiction specialists should be formally
recognized and incorporated into acute and community-
based health care settings [36].
Conclusions
Prescription opioid misuse remains a growing public
health concern for which urgent action is required to re-
define the problem at hand, develop evidence-based
guidelines, and scale up education for practitioners in
pain and addiction medicine. Further investigation into
the role of undertreated pain as a contributor to pre-
scription opioid misuse affords considerable opportunity
to reduce personal suffering and healthcare costs. There
are multiple avenues for intervention and research, and
if acted upon, much of the individual, social and structural
problems related to undertreated pain and prescription
opioid misuse could be meaningfully addressed.
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